Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological evaluation. The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Individual development of treatment programs for the treatment and management of the developmental carcinoma deficiency is required, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and multidimensional management.
In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, significant improvements have been made in many previously difficult-to-treat genetic metabolic disorders. Treatment needs to be closely monitored for efficacy and adverse reactions, with timely adjustments according to disease changes. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of prognosis associated with primary carcinoma deficiency.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.